What is Absolute Antibody?
Absolute Antibody operates at the intersection of biotechnology and precision engineering, specializing in the development of custom recombinant antibodies. The company provides a comprehensive suite of services, including antibody sequencing, expression, and protein engineering, which are vital for pharmaceutical companies and academic institutions alike. By focusing on reproducibility and high-quality standards, the firm addresses the industry-wide challenge of experimental variability. Their market position is defined by a robust portfolio of primary and secondary antibodies, which serve as the backbone for complex research applications and therapeutic development pipelines. Through advanced technical methodologies, they enable clients to accelerate their research timelines while maintaining stringent quality control protocols.
How much funding has Absolute Antibody raised?
Absolute Antibody has raised a total of $1.4M across 1 funding round:
Unspecified
$1.4M
Unspecified (2014): $1.4M, investors not publicly disclosed
Key Investors in Absolute Antibody
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Absolute Antibody?
With the support of this major strategic investment, Absolute Antibody is well-positioned to expand its technical infrastructure and broaden its service offerings. The company is expected to leverage this capital to enhance its proprietary engineering platforms, potentially integrating artificial intelligence or high-throughput screening technologies to further optimize antibody production. As the demand for specialized biologics continues to rise, the firm will likely focus on scaling its manufacturing capacity to support late-stage clinical trials and commercial-scale diagnostic needs. This growth trajectory suggests a transition toward becoming a dominant, full-service partner for global biopharma entities, ensuring that their recombinant solutions remain at the forefront of scientific innovation and therapeutic efficacy.
See full Absolute Antibody company page
